These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 9709939)
1. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. Orme SM; McNally RJ; Cartwright RA; Belchetz PE J Clin Endocrinol Metab; 1998 Aug; 83(8):2730-4. PubMed ID: 9709939 [TBL] [Abstract][Full Text] [Related]
2. The prevalence of benign and malignant tumors in patients with acromegaly at a single institute. Kurimoto M; Fukuda I; Hizuka N; Takano K Endocr J; 2008 Mar; 55(1):67-71. PubMed ID: 18202526 [TBL] [Abstract][Full Text] [Related]
3. Increased incidence of neoplasia in females with acromegaly. Cheung NW; Boyages SC Clin Endocrinol (Oxf); 1997 Sep; 47(3):323-7. PubMed ID: 9373454 [TBL] [Abstract][Full Text] [Related]
4. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. Ayuk J; Clayton RN; Holder G; Sheppard MC; Stewart PM; Bates AS J Clin Endocrinol Metab; 2004 Apr; 89(4):1613-7. PubMed ID: 15070920 [TBL] [Abstract][Full Text] [Related]
5. Incidence of malignant tumors in patients with acromegaly. Higuchi Y; Saeki N; Iuchi T; Uchino Y; Tatsuno I; Uchida D; Tanaka T; Noguchi Y; Nakamura S; Yasuda T; Yamaura A; Sunami K; Oka Y; Uozumi A Endocr J; 2000 Mar; 47 Suppl():S57-60. PubMed ID: 10890185 [TBL] [Abstract][Full Text] [Related]
8. Cancer Incidence in Patients With Acromegaly: A Cohort Study and Meta-Analysis of the Literature. Dal J; Leisner MZ; Hermansen K; Farkas DK; Bengtsen M; Kistorp C; Nielsen EH; Andersen M; Feldt-Rasmussen U; Dekkers OM; Sørensen HT; Jørgensen JOL J Clin Endocrinol Metab; 2018 Jun; 103(6):2182-2188. PubMed ID: 29590449 [TBL] [Abstract][Full Text] [Related]
10. ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. Sherlock M; Reulen RC; Alonso AA; Ayuk J; Clayton RN; Sheppard MC; Hawkins MM; Bates AS; Stewart PM J Clin Endocrinol Metab; 2009 Nov; 94(11):4216-23. PubMed ID: 19808848 [TBL] [Abstract][Full Text] [Related]
11. GH and mortality in acromegaly. Sheppard MC J Endocrinol Invest; 2005; 28(11 Suppl International):75-7. PubMed ID: 16625851 [TBL] [Abstract][Full Text] [Related]
12. Excess mortality in acromegaly. Holdaway IM Horm Res; 2007; 68 Suppl 5():166-72. PubMed ID: 18174739 [TBL] [Abstract][Full Text] [Related]
13. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly. Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288 [TBL] [Abstract][Full Text] [Related]
14. Cancer incidence and cause-specific mortality in male and female physicians: a cohort study in Estonia. Innos K; Rahu K; Baburin A; Rahu M Scand J Public Health; 2002; 30(2):133-40. PubMed ID: 12028862 [TBL] [Abstract][Full Text] [Related]
15. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. Swearingen B; Barker FG; Katznelson L; Biller BM; Grinspoon S; Klibanski A; Moayeri N; Black PM; Zervas NT J Clin Endocrinol Metab; 1998 Oct; 83(10):3419-26. PubMed ID: 9768641 [TBL] [Abstract][Full Text] [Related]
16. A cancer incidence and mortality study of Dow Chemical Canada Inc. manufacturing sites. Burns C; Harrison K; Jammer B; Zuccarini D; Lafrance B Occup Med (Lond); 2005 Dec; 55(8):618-24. PubMed ID: 16174663 [TBL] [Abstract][Full Text] [Related]